Yasuyuki Komiyama

Yasuyuki Komiyama

Auto-generated profile, based on publicly available information

Yasuyuki Komiyama

Department of Gastroenterology and Hepatology Faculty of Medicine University of Yamanashi Chuo Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in JGH Open
Verified
Journal Article
Open access
YKYasuyuki Komiyama
Yasuyuki Komiyama
NTNobuharu Tamaki
Nobuharu Tamaki
KTKeiji Tsuji
Keiji Tsuji
NMNami Mori
Nami Mori
TMToshie Mashiba
Toshie Mashiba
MKMasayuki Kurosaki
Masayuki Kurosaki
Aim: Although pemafibrate, a selective peroxisome proliferator‐activated receptor α (PPARα) modulator primarily prescribed for hypertriglyceridemia, may improve liver function in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), its efficacy has not been sufficiently evaluated. This study aimed to assess the effect of pemafibrate on liver function in patients with MASLD using a nationwide multicenter cohort.Methods: In this nationwide multicenter study, we analyzed 352 patients diagnosed with MASLD and hypertriglyceridemia who newly initiated pemafibrate therapy. The primary outcome was the rate of ALT normalization (ALT ≤ 30 U/L). Laboratory data were collected at baseline and 3, 6, and 12 months after pemafibrate initiation, and longitudinal changes were evaluated.Results: The mean ALT levels decreased significantly from 60.1 ± 1.8 U/L at baseline to 44.9 ± 1.4, 41.6 ± 1.3, and 38.1 ± 1.3 U/L at 3, 6, and 12 months, respectively (all p < 0.001). The ALT normalization rate increased from 30.4% at baseline to 46.0%, 50.9%, and 56.6% at 3, 6, and 12 months (p < 0.001), respectively, with marked improvement at three months and maintenance throughout follow‐up.Conclusions: Pemafibrate treatment significantly improved ALT levels and ALT normalization rates in MASLD patients with hypertriglyceridemia, with improvement observed at three months and a sustained effect up to 12 months. This is a large‐scale multicenter study to date evaluating pemafibrate in MASLD, providing robust evidence for its potential as a therapeutic option in this population.

11 September 2025 in Hepatology Research
Verified
Journal Article
Closed access
YKYasuyuki Komiyama
Yasuyuki Komiyama
MMMasaru Muraoka
Masaru Muraoka
TITetsuya Iijima
Tetsuya Iijima
LOLeona Osawa
Leona Osawa
HTHitomi Takada
Hitomi Takada
NENobuyuki Enomoto
Nobuyuki Enomoto